Investing.com - CTi Biopharma (NASDAQ: CTIC) reported first quarter EPS of $-0.110, better than the analyst estimate of $-0.111. Revenue for the quarter came in at $23.8M versus the consensus estimate of $22.95M.
CTi Biopharma's stock price closed at $8.940. It is up 69.000% in the last 3 months and up 112.860% in the last 12 months.
CTi Biopharma saw 0 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See CTi Biopharma's stock price’s past reactions to earnings here.
According to InvestingPro, CTi Biopharma's Financial Health score is "weak performance".
Check out CTi Biopharma's recent earnings performance, and CTi Biopharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar